- Home
- PTIX vs QLGN Comparison
PTIX vs QLGN Comparison
Compare PTIX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- QLGN
- Stock Information
- Founded
- PTIX 1994
- QLGN 1996
- Country
- PTIX United States
- QLGN United States
- Employees
- PTIX N/A
- QLGN N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- PTIX Health Care
- QLGN Health Care
- Exchange
- PTIX Nasdaq
- QLGN Nasdaq
- Market Cap
- PTIX 2.0M
- QLGN 2.4M
- IPO Year
- PTIX 2016
- QLGN N/A
- Fundamental
- Price
- PTIX $0.42
- QLGN $3.32
- Analyst Decision
- PTIX
- QLGN
- Analyst Count
- PTIX 0
- QLGN 0
- Target Price
- PTIX N/A
- QLGN N/A
- AVG Volume (30 Days)
- PTIX 324.0K
- QLGN 111.5K
- Earning Date
- PTIX 05-14-2025
- QLGN 04-15-2025
- Dividend Yield
- PTIX N/A
- QLGN N/A
- EPS Growth
- PTIX N/A
- QLGN N/A
- EPS
- PTIX N/A
- QLGN N/A
- Revenue
- PTIX N/A
- QLGN N/A
- Revenue This Year
- PTIX N/A
- QLGN N/A
- Revenue Next Year
- PTIX N/A
- QLGN N/A
- P/E Ratio
- PTIX N/A
- QLGN N/A
- Revenue Growth
- PTIX N/A
- QLGN N/A
- 52 Week Low
- PTIX $0.18
- QLGN $2.96
- 52 Week High
- PTIX $1.87
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- PTIX 67.76
- QLGN 44.88
- Support Level
- PTIX $0.18
- QLGN $3.06
- Resistance Level
- PTIX $0.28
- QLGN $3.78
- Average True Range (ATR)
- PTIX 0.04
- QLGN 0.28
- MACD
- PTIX 0.01
- QLGN 0.03
- Stochastic Oscillator
- PTIX 62.39
- QLGN 19.80
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.